Hepatology

Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis

M Marzioni¹, G Alpini², S Saccomanno¹, C Candelaresi¹, J Venter³, C Rychlicki¹, G Fava¹, H Francis⁴, L Trozzi¹, A Benedetti¹

¹ Department of Gastroenterology, Università Politecnica delle Marche, Ancona, Italy
² Central Texas Veterans Health Care System, and The Texas A & M Health Science Center College of Medicine, Temple, Texas, USA
³ Department of Medicine, Scott & White Hospital and The Texas A & M University System Health Science Center College of Medicine, Temple, Texas, USA
⁴ Scott & White Hospital, Temple, Texas, USA

Dr M Marzioni, Department of Gastroenterology, Università Politecnica delle Marche, Nuovo Polo Didattico, Via Tronto 10, 60020 Ancona, Italy; m.marzioni{at}univpm.it

Background and aims: Progression of chronic cholestatic disorders towards ductopenia results from the dysregulation of cholangiocyte survival, with cell death by apoptosis prevailing over compensatory proliferation. Currently, no therapy is available to sustain cholangiocyte survival in the course of those disorders. It was recently shown that cholangiocytes express the glucagon-like peptide-1 receptor (GLP-1R); its activation results in enhanced proliferative reaction to cholestasis. The GLP-1R selective agonist exendin-4 sustains pancreatic β cell proliferation and prevents cell death by apoptosis. Exendin-4 is now employed in humans as a novel therapy for diabetes. The aim of the present study was to verify whether exendin-4 is effective in preventing cholangiocyte apoptosis.

Methods: In vitro, tests were carried out to determine if exendin-4 is able to prevent apoptosis of cholangiocytes isolated from normal rats induced by glycochenodeoxycholic acid (GCDCA); in vivo, animals subjected to 1 week of bile duct ligation and to a single intraperitoneal injection of CCl₄ were treated with exendin-4 for 3 days.

Results: Exendin-4 prevented GCDCA-induced Bax mitochondrial translocation, cytochrome c release and an increase in caspase 3 activity. Phosphatidylinositol 3-kinase, but not cAMP/protein kinase A or Ca²⁺/calmodulin-dependent protein kinase inhibitors, neutralised the effects of exendin-4. In vivo, exendin-4 administration prevented the increase in TUNEL (terminal deoxynucleotidyl transferase-mediated triphosphate end-labelling)-positive cholangiocytes and the loss of bile ducts observed in bile duct-ligated rats treated with CCl₄.

Conclusion: Exendin-4 prevents cholangiocyte apoptosis both in vitro and in vivo; such an effect is due to the ability of exendin-4 to counteract the activation of the mitochondrial pathway of apoptosis. These findings support the hypothesis that exendin-4 may be effective in slowing down the progression of cholangiopathies to ductopenia.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

GLP-1 analogues: a new therapeutic approach to prevent ductopenia in cholangiopathies?

Ulrich Beuers and Burkhard Göke
Gut 2009 58: 902-903. [Extract] [Full Text] [PDF]